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PRECLINICAL RESEARCH
haracterization of Beta3-Adrenoceptors in
uman Internal Mammary Artery and Putative
nvolvement in Coronary Artery Bypass Management
ertrand Rozec, MD,*† Sabrina Serpillon, PHD,* Gilles Toumaniantz, PHD,* Camille Sèze, MSC,*
ohann Rautureau, PHD,‡ Olivier Baron, MD,§ Jacques Noireaud, PHD,* Chantal Gauthier, PHD*
antes, France; and London, United Kingdom
OBJECTIVES The aim of the present study was to analyze whether beta3-adrenoceptors (3-ARs) were
effectively present and functional in the human internal mammary artery (IMA).
BACKGROUND The beta1- and beta2-adrenoceptors classically mediate the relaxant effects of catecholamines
in the vessels. In vitro and in vivo studies performed in various animal species described
vasodilating effects due to activation of a third beta-ARs subtype (3).
METHODS Reverse transcription-polymerase chain reaction analysis, Western blot experiments, and
pharmacological studies were carried out in human IMA samples harvested from 27 patients
undergoing coronary bypass surgery.
RESULTS The 3-ARs messenger ribonucleic acid and protein were detected in intact IMA, but were
absent in endothelium-free samples. This finding was confirmed by immunohistochemical
experiments. In organ baths, a 3-AR agonist, SR 58611A, induced an endothelium-
dependent relaxation of phenylephrine-precontracted IMA rings. This vasodilation was not
modified by 1/2-AR antagonists, but was greatly altered in the presence of L-748,337, a
selective human 3-AR antagonist. Moreover, the inhibition of nitric oxide (NO) synthases
abolished the 3-adrenergic vasodilation, suggesting the involvement of a NO-signaling
pathway.
CONCLUSIONS Those results demonstrated the presence of 3-ARs in the endothelial layer of human IMA.
The present work highlights the role of 3-ARs in vasomotor control of IMA and opens new
fields of investigation in coronary bypass graft management, heart failure, and
hypertension. (J Am Coll Cardiol 2005;46:351–9) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.061Cardiology Foundation
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phe sympathetic nervous system is the central network of
he neurohumoral regulation of vascular tone. Stimulation
f beta-adrenoceptors (-ARs) leads to a relaxation of the
ascular smooth muscle, thereby controlling the blood flow
istribution in different organs. Since the classification
stablished by Lands et al. (1), -ARs have been pharma-
ologically classified into 1 and 2-AR subtypes. Although
oth 1-and 2-ARs are involved in vasodilation, the role of
ach subtype varies depending on species and vascular beds
2). In cerebral and coronary arteries, 1-ARs predominate
n contrast to the mesenteric, pulmonary, and muscular
essels, where 2-ARs largely predominate (2). The role of
ndothelium in the vasodilating effect of -AR agonists also
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ciences et Techniques, Université de Nantes, Nantes, France. This work was
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Fondation de France,” and the “Fondation Langlois.” Bertrand Rozec was supported
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Fondation de la Recherche Médicale.” Sabrina Serpillon was supported by the
Conseil Général de Loire-Atlantique.” Drs. Rozec, Serpillon, and Toumaniantz
ontributed equally to this work.h
Manuscript received December 16, 2004; revised manuscript received March 22,
005, accepted March 29, 2005.aries with the species and the vascular bed. Thus, in
umans, isoprenaline, a nonspecific -AR agonist, induced
vasodilation in umbilical vein by stimulating endothelial
2-ARs (3), whereas the relaxation of internal mammary
rtery (IMA) and saphenous vein was shown to be mediated
ia 2-AR located on the smooth muscle (4).
During the 1980s, the classification of -ARs was chal-
enged because of atypical effect of -AR agonists in some
issues such as heart, fat, and digestive tract. The receptor
nvolved in non-1- and/or non-2-AR effects was first
escribed as atypical -AR. Later on, a new -AR subtype,
3, was cloned (5) and a low-affinity site for the 1-AR
dentified (6). The participation of a third -AR in vasore-
axation was suggested by in vitro and in vivo studies.
soprenaline induced a vasodilation resistant to propranolol
a nonspecific -AR antagonist) in rat carotid artery (7),
orta (8), pulmonary vessels (9), and in canine pulmonary
rtery (10). The use of preferential 3-AR agonists con-
rmed these findings (7,8,11). Recently, an in vitro study in
uman coronary microarteries reported that a preferential
3-AR agonist produced a vasodilation involving both nitric
xide (NO) and endothelial-derived hyperpolarizing factor
athway (12). In vivo studies have also suggested the
resence of functional 3-ARs in vessels, but their role was
ighly species-dependent. Thus, in conscious dogs, 3-AR
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3-Adrenoceptors in Human Internal Mammary Arteries July 19, 2005:351–9gonists induced a peripheral vasodilation, primarily in skin
nd adipose tissues (13,14); 3-AR stimulation was shown
o be less important in rats than in dogs, and essentially
bsent in nonhuman primates (15). In humans, the 3-AR
layed a weaker role in the control of blood flow in adipose
issue than 1- and 2-AR (16). There is also a great
ariability of the signaling pathways according to the species
nd the vascular bed studied. A cAMP-dependent pathway
eemed to be involved in the 3-adrenergic effect in canine
ulmonary artery (10) and rat portal vein myocytes (17). In
at thoracic aorta, the stimulation of endothelial 3-ARs
ctivated an endothelial NO synthase leading to an increase
f intracellular cGMP (11) and an activation of several
otassium channels (BKCa, KATP, Kv) of the vascular
mooth muscle cells (18).
The IMA is the preferred bypass graft for myocardial
evascularization owing to superior graft patency and in-
reased long-term survival compared with saphenous vein
rafts (19,20). However, the IMA has a greater tendency to
pasm leading to a perioperative increase in morbidity and
ortality. The vasoconstriction can be evoked by several
timuli such as mechanical trauma, nerve stimulation, and
asoconstrictor substances. Circulating sympathomimetic
ubstances are considered as possible spasmogenic agents
21). The knowledge of the IMA pharmacology and phys-
ology is, therefore, essential to treat and to prevent the
asospasm. In this regard, several projects have been carried
ut on the IMA, in order to analyze alpha-adrenoceptors
-AR) physiology (subtypes, function, regulation by age)
22,23). By contrast, although -blockers are widely used in
he treatment of ischemic cardiopathy, only few works
valuated the presence and the possible role of the different
-AR subtypes. Molenaar et al. (4) reported the predomi-
ant role of 2-ARs in the isoproterenol induced-
asodilation in the IMA. Consequently, the aim of the
resent study was to characterize by molecular, biochemical,
nd pharmacological approaches the presence of 3-AR in
he human IMA. Then we discuss possible functional roles
f 3-ARs, effectively present in endothelial layer of the
MA, in physiological and/or pathophysiological condi-
ions. Finally, clinical implications of our study are pointed
Abbreviations and Acronyms
Ach  acetylcholine
CABG  coronary artery bypass graft
IMA  internal mammary artery
LIPE  hormone-sensitive lipase
L-NMMA  NG-monomethyl-L-arginine monoacetate
NO  nitric oxide
PE  phenylephrine
RT-PCR  reverse transcription-polymerase chain
reaction
-AR  alpha-adrenoceptor
-AR  beta-adrenoceptorut. AETHODS
issue origin. Human IMA samples were harvested from
7 patients undergoing coronary bypass surgery. There were
5 men and 2 women with an age of 68.2  7.5 years, body
eight 75.7  10.3 kg (mean  SD). All suffered from
oronaropathy (New York Heart Association functional
lass [angina pectoris] II to III) but without apparent heart
ailure. Their clinical characteristics are detailed in Table 1.
he discarded distal IMA segments proximal to the bifur-
ation were collected during the operation and immediately
laced in Tyrode solution composed as follows (mM):
aCl, 130; KCl, 5.6; MgCl2, 1; CaCl2, 2; glucose, 11;
EPES, 8; pH was adjusted to 7.4. The samples were
ransferred to the laboratory within 4 h.
NA preparations. Total RNAs were extracted from hu-
an IMA without adventice by a modification of the acid
uanidium-thiocyanate-phenol-chloroform method, as pre-
iously described by Chomczynski and Sacchi (24). Briefly,
he vessels were homogenized with an ultra-turrax homog-
nizer in Trizol solution (Gibco BRL, Villiers-Le-Bel,
rance). After centrifugation and precipitation by addition
f isopropanol, the RNA pellets were washed with 75%
thanol and resuspended in RNAse-free water. The con-
entrations were determined spectrophotometrically at 260
m, and the integrity of the RNA was verified on 0.8%
ris-acetate EDTA agarose gels.
everse transcription-polymerase chain reaction (RT-
CR) experiments. The oligonucleotides were purchased
rom Genosis (Cambridgeshire, United Kingdom). Se-
uences of the different primers are reported in Table 2.
irst-strand synthesis of cDNA from total RNAs was
arried out using moloney murine leukemia virus reverse
ranscriptase (Gibco BRL) with oligo(dT) (Sigma, L’Isle
’Abeau Chesnes, France). The single strand cDNAs were
ubsequently amplified by polymerase chain reaction using
aq DNA polymerase (Pharmacia, Saclay, France). Each
olymerase chain reaction experiment included a negative
ontrol consisting of a reverse transcriptase reaction con-
aining no added enzyme and positive controls correspond-
able 1. Clinical Characteristics of Patients
ge (yrs) 68.2  7.5
ender ratio (M/F) (25/2)
ody weight (kg) 75.7  10.3
ssociated pathologies
Aortic valvular stenosis 2
Mitral valvular insufficiency 2
Hypercholesterolemia 16
Type II diabetes mellitus 9
Systemic hypertension 7
rug regimens
Beta-blockers 21
Calcium-blockers 11
Nitrates 13
ACE inhibitors 9
Diuretics 8
Statins 13CE  angiotensin-converting enzyme.
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July 19, 2005:351–9 3-Adrenoceptors in Human Internal Mammary Arteriesng to genomic DNA or fat cDNA. After initial heating of
amples at 94°C for 5 min, each cycle of amplification
onsisted of 1 min at 92°C, 1 min at annealing temperature
ppropriate for the primers used, and 1 min at 72°C.
nnealing temperatures were 56°C for all primers. After 40
ycles of amplification, the polymerase chain reaction prod-
cts were separated through a 2% TAE agarose gel and
isualized under ultraviolet light after staining with
thidium bromide.
estern blotting experiments. The expression of the
3-AR was examined with a monoclonal antibody raised
gainst the human isoform of the receptor (25). Human
MAs were cut in rings. For some rings, the endothelium
as removed by gently rubbing the intimal surface with a
ne pair of small forceps. Protein fractions (100 g) with
r without endothelium were denatured with 5%
-mercaptoethanol in Laemmli’s sample buffer and elec-
rophoresed on 10% polyacrylamide/SDS gels and trans-
erred onto a hybond C super membrane (Amersham,
aclay, France) using an electroblotting apparatus (Bio-
ad, Marnes La Coquette, France). The protein amount
as checked by staining with Coomassie. Nonspecific
inding was blocked by incubating membranes in nonfat
ry milk 5% in TBS. Then they were incubated in milk
ith 1% TBS alone or with the primary antiserum,
ashed in TBST (TBS containing 0.1% Tween 20), and
ybridized with the secondary antibody anti-IgG peroxy-
ase conjugate (Sigma). The membranes were washed
ith TBS, and antibody complexes were revealed by
he enhanced chemiluminescence detection procedure
Amersham).
mmunohistochemistry analysis. Fixation and tissue pro-
essing protocols were performed as described previously
18). After freezing in 2-methyl butane solution (50°C),
0-mol/l sections of human IMA were cut on cryostat
icrotome and stored at20°C until using. The expression
f the 3-AR was examined with the same antibody used for
he Western blotting experiments. The sections were incu-
ated with the primary antibody or with buffer alone as
ontrol of specificity for the human 3-AR antiserum
human 3-AR Ab), washed, and incubated with the
able 2. Oligonucleotides Used as Primers for PCR Reaction
Name Length Strand
1A-AR-S 23 Forward 5= TGATTTC
1A-AR-AS 23 Reverse 5= ATGTCCT
1-AR-S 17 Forward 5= GCTGCAG
1-AR-AS 17 Reverse 5= GCGAGGT
2-AR-S 20 Forward 5= CACAGCC
2-AR-AS 21 Reverse 5= CGGGCCT
3-AR-S 17 Forward 5= ACCTGGC
3-AR-AS 20 Reverse 5= ACTGGCT
IPE-S 17 Forward 5= GCTCAAC
IPE-AS 19 Reverse 5= AAGGGGT
CR  polymerase chain reaction.econdary antibody. After the secondary hybridization with sn anti-rat IgG peroxidase conjugated developed in rabbit
Sigma), the antibody complexes were revealed for sensitive
etection of the enzymatic activity with peroxydase sub-
trate kit AEC (SK4200, Vector, AbCys SA, Paris, France).
harmacological studies. The vessels were carefully
leared of fat and connective tissue and cut into 4-mm-long
ings. In some rings, the endothelium was removed by
entle rubbing of the intimal surface with a fine pair of small
orceps. They were suspended on stainless steel wires in a
0-ml organ bath containing Krebs solution composed as
ollows (mmol/l): NaCl, 118; KCl, 4.7; MgSO4, 1.2;
H2PO4, 1.2; NaHCO3, 25; EDTA (ethylenediaminetet-
aacetic acid), 0.016; glucose, 11.1; and CaCl2, 2.5; pH 7.4.
ath temperature was maintained at 37°C, and the Krebs
olution was continuously oxygenated with a 95% O2, 5%
O2 gas mixture. Isometric tension was recorded by a force
isplacement transducer (IT2, EMKA Technologies, Paris,
rance) and displayed on a computer (IOX software,
MKA Technologies). Data were analyzed using Datana-
yst software (EMKA Technologies). After a 30-min equil-
bration period, rings were progressively stretched to a
esting tension of 2.5 g (this resting tension was determined
n preliminary studies to obtain steady and reproducible
ontractions). The rings were then challenged twice with
Cl (90 mmol/l) with a 15-min interval to ensure that
esponses were reproducible. After a further 30-min equil-
bration period, rings were precontracted to 2.5 g at least
ith 1 mol/l phenylephrine (PE), and functional endo-
helium was checked by the presence of at least 50%
elaxation with 1 mol/l acetylcholine (Ach). In denuded
ascular rings, endothelium removal was confirmed by the
bsence of Ach-induced relaxation. Arterial rings were
ontracted again with 1 mol/l PE after another 30-min
quilibration period. A cumulative concentration-response
urve to SR 58611A (a preferential 3-AR agonist) was
hen constructed. In some experiments, rings were equili-
rated in Krebs containing 10 mol/l nadolol (a 1- and
2-AR antagonist), 3 mol/l L-748,337 (a 3-AR antago-
ist), or 100 mol/l NG-monomethyl-L-arginine monoac-
tate (L-NMMA; a NO synthase inhibitor), for 30 min
efore PE application. Control rings were only treated by
quence
Number of
Cycles
Amplification
Size
CCCTCTGAAACAG 3= 40 224 pb
GTTGCCCTTCCAC 3=
CTCACCA 3= 40 212 pb
GGTCCAG 3=
GCCAAGTTCG 3= 40 287 pb
TCTTGGTCAGC 3=
GACCAAC 3= 40 122 pb
GATGGGCGC 3=
TTCCTGG 3= 40 459 pb
TGACTATGG 3=Se
AAG
TGT
ACG
AGC
ATT
TAT
TGT
CAT
TCC
TCTolvent during this period. Relaxation produced by each
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3-Adrenoceptors in Human Internal Mammary Arteries July 19, 2005:351–9oncentration of the 3-AR agonist was measured after a
teady-state was reached. As SR 58611A induced long-
asting relaxation, spontaneous time-dependent relaxation
as taken into account by systematic subtraction of the
orresponding spontaneous relaxation obtained in a control
ascular ring taken from the same IMA segments. Values
ere expressed as the percentage change in the maximal
ension of the vessel rings after addition of 1 mol/l PE.
ata and statistical analysis. Results were expressed as the
ean  SEM of n experiments. The resting tension, the
ontractile response to 1 mol/l PE, and the Ach-induced
elaxation (up to 50%) obtained in the different protocols
ere compared using a Student t test. The statistical
ignificance of a drug effect was assessed using a one-way
nalysis of variance (ANOVA) followed by a Dunnett’s test.
omparison of the different concentration-response curves
as performed by a two-way ANOVA (concentration,
reatment) with repeated measures completed when appro-
riate by a Bonferroni t test. A p value 0.05 was
onsidered statistically significant.
rugs. L-PE hydrochloride, Ach chloride, nadolol, and
-NMMA were obtained from Sigma. SR 58611A, [(RS)-
-[(25)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahy-
ronapht-2-yl]-(2)-2-(3-chlorophenyl)-2 hydroethana-
ide hydrochloride], and L-748,337, (S)-N-[4-[2-[[3-
3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]
thyl]phenyl]benzenesulfonamide were generous gifts from
anofi-Synthélabo (Montpellier, France) and Merck
Rahway, New Jersey), respectively. All drugs were pre-
igure 1. Detection by reverse transcription (RT) polymerase chain reaction
nd 3-ARs, and hormone-sensitive lipase (LIPE) gene transcripts in hum
ragments were separated on a 2% agarose gel and visualized by staining
ndicated on the middle of the panels. This experiment is representative of
DNg  genomic DNA; AR-AS  reverse strand; AR-S  forward str
one RT.ared as stock solution in distilled water, with the exception rf nadolol, which was dissolved in hydrochloric acid before
eing neutralized to pH 7.4 with NaOH 1N and
-748,337, which was dissolved in dimethylsulfoxide
Sigma). The final concentration of the solvent in the organ
ath was less than 0.1% v.v1 and was checked to produce
o effect on the tissue response.
ESULTS
etection of 3-AR mRNA in IMA. The main purpose
f this study was to compare semiquantitatively the amount
f the different adrenoceptor subtypes (1A-, 1-, 2-, and
3-ARs) in the same preparation of first-strand synthesis of
DNA from IMA. The present finding demonstrates that
he 1A- and 2-ARs were strongly expressed in IMA,
hile 1- and 3-ARs were expressed at low level in this
essel (Fig. 1A). Furthermore, the RT-PCR analysis indi-
ated that expected amplified products of 122 base pairs (bp)
ith the human 3-AR primer couple could be identified by
thidium bromide staining for the amplified samples of
enomic DNA (positive control) and for human IMA
NAs (Figs. 1A and 1B). As expected, no signal was
bserved when the RNA samples were not reverse tran-
cripted into cDNA and directly used for the different
olymerase chain reaction experiments. As this receptor is
resent in the adipose tissues, hormone-sensitive lipase
LIPE) marker was tested to check a fat contamination in
ur preparations. The RT-PCR analysis with the LIPE
rimer couple indicated an expected polymerase chain
uman 1A-adrenoceptors (1A-ARs), 1-adrenoceptors (1-AR), 2-ARs,
ternal mammary artery (IMA) and white adipose tissue. Amplified cDNA
ethidium bromide. Sizes of the polymerase chain reaction products are
investigations performed on three vessels obtained from different patients.
fat  human fat; M  100 pb ladder (Biolabs, New England); NRT of h
an in
with
threeeaction product of 459 bp for amplified samples of white
a
U

W
a
o
p
f
A
h
d
c
p
d

I
r
h
m
w
s
3
o
i
t
m
I
P
s
r
5
d

l
4

a
T
1
s
a
w
i
(
t
e
n
a
r
F
w
e
e
F
(
s
h
c
i
355JACC Vol. 46, No. 2, 2005 Rozec et al.
July 19, 2005:351–9 3-Adrenoceptors in Human Internal Mammary Arteriesdipose tissue, but not for the IMA preparation (Fig. 1C).
nder these conditions, the mRNAs encoding for human
3-AR were still present (Figs. 1A and 1B).
estern blotting experiments. Western blot probed with
n antibody directed against human 3-AR showed a band
f roughly 55 kDa with a strong intensity for the total
rotein fraction of human IMA and at the limit of detection
or the sample where the endothelium was removed (Fig. 2).
s expected, no reactivity was observed in the absence of the
uman 3-AR serum. The protein amount between the
ifferent conditions, with or without endothelium, could be
hecked by the staining only due to the secondary antibody
eroxydase conjugate complexes that were revealed by the
etection procedure for the incubation without the human
3-AR serum (Fig. 2).
mmunohistochemistry analysis. The serum antibody
aised against the human 3-AR was used for an immuno-
istochemical analysis. The pattern of human 3-AR im-
unoreactivity was compared with the profile obtained
ithout primary antiserum. The human 3-AR Ab highly
tained cells from the endothelial layer of IMA (Figs. 3Bb,
Dd, and 3Ff), and a light and diffuse signal was only
bserved in the smooth muscle layer. Furthermore, the
ncubation without the primary antibody totally abolished
he staining observed in the endothelial layer but did not
odify the staining obtained in the smooth muscle layer of
MA (Figs. 3Aa, 3Cc, and 3Ee).
harmacological study. All IMA groups of the present
tudy presented no significant difference in contractile
esponses to 1 mol/l PE and Ach-induced relaxations. SR
8611A (0.1 to 30 mol/l) induced a concentration-
ependent relaxation of IMA rings contracted with 1
mol/l PE (Fig. 4). The relaxing effect reached its maximal
evel after 10 to 15 min of exposure to SR 58611A (Fig.
A). Because of the long-lasting relaxation induced by
3-AR agonists, the spontaneous time-dependent relax-
tion had to be evaluated in control rings for each protocol.
he maximum spontaneous relaxation was measured to be
4.5  5.7% during SR 58611A experiments (n 6). After
ubstraction of the spontaneous relaxation, the vasorelax-
igure 2. Western blot analysis of human beta3-adrenoceptor (3-AR) expr
as incubated without (left panel) or with antihuman 3-AR antibody (A
xperiment is representative of five investigations performed on five vesse
ndo.  without endothelium.tion obtained in the presence of 30 mol/l of SR 58611A
B
as weaker (Emax: 35.1  5.9%, n  6) than the one
nduced by a submaximal concentration (1 mol/l) of Ach
Emax: 79.8 2.3%, n 50) (Fig. 4A). In order to confirm
hat SR 58611A activated effectively 3-ARs, additional
xperiments were performed in the presence of either
adolol, a specific 1- and 2-AR antagonist, or L-748,337,
specific human 3-AR antagonist. The concentration-
esponse curve to SR 58611A was not modified by a 30-min
in internal mammary artery with or without endothelium. The membrane
ght panel) and revealed by chemiluminescence detection procedure. This
ained from different patients. With endo.  with endothelium; Without
igure 3. Immunohistochemistry analysis of human beta3-adrenoceptors
h3-AR) expression in internal mammary artery. Adjacent 10-m thick
ections were incubated without (A, C, E, a, c, and e) or with anti-
3-AR antibody (Ab) (B, D, F, b, d, and f ) revealed by peroxydase-
onjugated second antiserum. This experiment is representative of three
nvestigations performed on three vessels obtained from different patients.ession
b) (ri
ls obtlack arrowhead shows interesting areas at low magnitude (micrographs
20) that were further observed at high magnitude (micrographs 60).
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3-Adrenoceptors in Human Internal Mammary Arteries July 19, 2005:351–9retreatment with 10 mol/l nadolol (Emax  40.3 
.1%, n  6) (Fig. 4B), but was markedly reduced in the
resence of 3 mol/l L-748,337 (two-way ANOVA: p 
.001; Emax  10.5  7.7%, n  6; Fig. 4B). The
oncentration-response of SR 58611A was significantly
lunted after endothelium removal (two-way ANOVA: p
.01; Emax 6.8 6.3, n 5, Fig. 5). On the basis of this
esult, the involvement of the NO pathway in the SR
8611A-induced relaxation was investigated by incubating
MA rings with 100 mol/l L-NMMA. In such conditions,
he relaxant effect of SR 58611A was abolished (two-way
NOVA p  0.001). The Emax value obtained at 30
mol/l SR 58611A was 4.3  6.9% (n  6; p  0.05 vs. 30
mol/l SR 58611A alone) (Fig. 5).
ISCUSSION
y complementary approaches of molecular biology, bio-
hemistry, and pharmacology, we have shown the presence
f functional endothelial 3-ARs to be responsible for a
asodilation involving the NO pathway in the human IMA.
The 3-AR transcripts were clearly detected in human
igure 4. Effect of beta3-adrenoceptor (3-AR) agonists in human internal
ammary arteries (IMA). (A) Typical records of relaxant effect of SR
8611A, a preferential 3-AR agonist, and acetylcholine (1 mol/l) in
uman IMA rings. (B) Concentration-response curves to SR 58611A
erformed in the absence or in the presence of 10 mol/l nadolol, an 1
nd 2-AR antagonist, and 3 mol/l L-748,337, a human 3-AR
ntagonist, in human IMA rings constricted with 1 mol/l phenylephrine.
he mean curves resulting from subtraction of the spontaneous relaxation
f control vessels are shown. Results are expressed as percentage of
elaxation from the contraction level induced by phenylephrine. Each point
s the mean value of six experiments, and error bars represent SEM. *p 
.05 and **p  0.01 indicate significant differences from response to SR
8611A alone.MA preparations by RT-PCR. Their expression was sim-
m
ilar to that of 1-ARs, but lower than 2-ARs. As 3-ARs
re also present in adipose tissues, LIPE marker was used to
heck for fat contamination; LIPE is highly expressed in
hite adipose tissue and steroidogenic tissues, with lower
mounts expressed in cardiac and skeletal muscles, macro-
hages, and islets of Langerhans (26). In our conditions, no
pecific products corresponding to LIPE were detected with
everse transcription performed in IMA samples. Thus,
hese results indicated that the expression of the 3-AR in
MA was not due to the presence of adipocytes and/or
acrophages. In addition, the present work showed that
estern blotting pattern of human monoclonal 3-AR
ntibody revealed a strong labeling for the total protein
raction of IMA. The labeling was almost undetectable in
amples where the endothelium was removed. Thus, expres-
ion of 3-AR was mainly located in endothelial layer and
lmost absent in smooth muscle cells. In the same way,
mmunohistochemical analysis performed in intact IMA
emonstrated a strong staining in the endothelial layer with
uman 3-AR antibody (that did not appear when the
rimary antiserum was not incubated). By contrast, the
bsence of staining observed in the smooth muscle layer
uggested the lack or a very low level (under the limit of
etection of the procedure used) of 3-AR expression in
mooth muscle cells. In a recent study using the same
onoclonal antibody, an endothelial localization of 3-AR
as also reported in human coronary arteries (12). Con-
ersely, in human gastrointestinal arteries, immunohisto-
hemistry with an antipeptide polyclonal antibody revealed
3-AR expression localized in smooth muscle cells, but
ot in the endothelial layer (27). Thus, localization of
igure 5. Effect of NG-monomethyl-L-arginine monoacetate (L-
MMA) treatment or endothelium removal on SR 58611A-induced
asodilation in human internal mammary artery rings constricted with 1
m phenylephrine (PE). Concentration-response curves to SR 58611A
ere performed in the absence or in the presence of 100 mol/l
-NMMA, an inhibitor of nitric oxide synthases, or after endothelium
emoval. The mean curves resulting from subtraction of the spontaneous
elaxation of control vessels are shown. Results are expressed as percentage
f relaxation from the contraction level induced by PE. Each point is the
ean value of six experiments, and error bars represent SEM. **p  0.01
ndicates significant differences from response to SR 58611A alone.
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July 19, 2005:351–9 3-Adrenoceptors in Human Internal Mammary Arteries3-AR in vascular wall might be different according to the
ascular beds. In other species, only two studies performed
n rat vessels (portal vein and thoracic aorta) reported the
xpression of 3-AR mRNA. These studies also reported a
ifferential localization of 3-AR according to vascular bed:
mooth muscle cells in portal vein (17) and endothelial cells
n thoracic aorta (18).
In the present work, the presence of 3-AR in human IMA
as also confirmed by a pharmacological approach. SR
8611A, a preferential 3-AR agonist, induced a slow and
eak relaxation. The relaxation induced by SR 58611A was
ot modified by a pretreatment with nadolol, a 1- and 2-AR
ntagonist, but was greatly reduced by L-748,337, a selective
uman 3-AR antagonist (28). Albeit, it was impossible to
etermine the pD2 values from the concentration-response
urves of SR 58611A, it appeared that this compound pro-
uced an effect for relatively high concentrations suggesting a
ow potency for the 3-AR agonists in human IMA. Of
nterest, similar slower kinetics were described for the relaxing
ffect of 3-AR agonists in other conductive vessels (rat
horacic aorta [11]; rat carotid arteries [7]) as well as in the
mooth muscle of the rat gastrointestinal tract (29,30). How-
ver, the potency of the 3-AR agonists was lower in vessels
han in the gastrointestinal tract. In resistive vessels like human
oronary arteries, the potency of 3-AR agonist was higher
12). It is still unclear why 3-adrenoceptor agonists have poor
otency for conductive vessel relaxation. In other tissues, like
dipose tissues and the heart, the potency of 3-AR agonists
as higher than in vessels, around 10 to 100 nM. Moreover,
oncerning the signaling pathway involved in the 3-AR-
nduced relaxation, endothelium removal strongly attenuated
he vasodilating effect of the SR 58611A. In the same way, a
retreatment with L-NMMA, a NO-synthase inhibitor, al-
ost abolished the SR 58611A-induced relaxation. These data
trengthened the endothelial localization of 3-AR in human
MA and suggested the involvement of the NO-synthase
ignaling pathway in the 3-AR-induced vasorelaxation.
In the same model of human IMA, a previous study
uggested the coexistence of three distinct -AR subtypes
31). Cyanopindolol, a partial 3-AR agonist, and BRL
7344, a preferential 3-AR agonist, induced vasorelaxant
ffects in endothelium-denuded IMA segments precon-
racted with PE. In denuded IMA rings, the isoproterenol-
nduced relaxation was partially inhibited by propranolol
nly in a minority group of IMA segments, whereas
yanopindolol-induced vasodilation was completely resis-
ant to blockade by propranolol, a -AR nonselective
ntagonist. However, that study was incomplete because
1/2-AR antagonists, such as propranolol or nadolol and
elective 3-AR antagonists, were not tested on the BRL
7344-induced relaxation, nor the involvement of endothe-
ium in the relaxant effect induced by 3-AR stimulation.
imilar results were obtained by He et al. (32) that showed
hat isoproterenol produced a weak relaxation (24  5%).
he vasodilation was only partially antagonized by propran-
lol (about 50%), suggesting an atypical -adrenergic effect. bhese latter authors also showed that isoproterenol-induced
elaxation was less important in IMA rings precontracted
ith potassium instead of U46619. In addition, the vasodi-
ation was completely abolished in the presence of propran-
lol. Those results could be explained by our own previous
orks performed in rat thoracic aorta, which showed the
nvolvement of several types of potassium channels in the
3-AR-mediated relaxation (18). The study performed by
e et al. (32) being old, it was not possible at this period to
uspect a putative involvement of 3-ARs in the observed
ffects. Indeed, 3-AR was cloned in 1989 (5). All those
ata strengthened our results on the functional presence of
3-ARs in the human IMA. However, in our study, the
ctivation of 3-ARs by an endogenous catecholamine was
ot investigated, which represents a limitation of the
resent study. In another human vascular bed, coronary
icroarteries, BRL37344 also produced a vasorelaxation
hat was not modified by nadolol, but was blunted in the
resence of bupranolol, a nonspecific -AR antagonist (12).
n that vascular bed, functional 3-ARs were also located in
ndothelial cells, and their stimulation activated both the
O and the endothelial-derived hyperpolarizing factor
athway (12).
The development of IMA grafting is the most remarkable
chievement in coronary artery surgery in the past two
ecades. The knowledge of the pharmacology of the vascu-
ar grafts allows a new approach in the drug management of
ypass operated patients. Given the presence of 3-AR in
icrocoronary arteries and its relative resistance to homol-
gous desensitization, the relaxing effect of 3-AR agonists
ould be interesting in the management after coronary
rtery bypass graft (CABG) of ischemic patients who often
resent an increased adrenergic tone (32,33).
After coronary artery bypass, the vascular -AR responses
re markedly abnormal, due in part to the exposure of
essels to endogenous catecholamines in cerebral arteries
33,34) and pulmonary vascular bed (34,35), for instance.
everal mechanisms were suggested to explain -ARs dys-
unction after coronary artery bypass: 1) uncoupling of
-ARs from the Gs-protein-adenylate cyclase complex
attributed to the rapid phosphorylation of the receptor;
nd/or 2) impairment of the adenylyl cyclase moiety (36,37).
y contrast, 3-ARs are only activated by high concentra-
ions of catecholamines such as isoproterenol (38). Further-
ore, 3-ARs have been shown to be relatively resistant to
esensitization (39). On one hand, the effect of 3-AR
timulation could increase the graft and the coronary flow
fter CABG. On the other hand, the surprising negative
notropic effect induced by 3-AR agonists in the human
eart could reduce the myocardial oxygen consumption
40). It may result in an improvement of the heart oxygen
upply/consumption ratio and, thus, accommodate for a
educed perfusion. In this context, the potential role of
3-AR in perioperative period of CABG might be worth
eing explored.
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3-Adrenoceptors in Human Internal Mammary Arteries July 19, 2005:351–9The IMA malperfusion syndrome is a critical complica-
ion of CABG (1.9% and up to 20% after primary coronary
ypass and reoperation, respectively) and can have devastat-
ng effects on the outcome of a cardiac operation (41). The
tiology of the syndrome is multifactorial, but a spasm of the
raft has been frequently suggested, and, thus, the treatment
mplicated the use of vasodilator and inotropic drugs (42).
owever, the vasoconstrictive effects of inotropic substances
ould reduce arterial graft flow and worsen the situation
43). By the way, when -AR agonists were nevertheless
sed in the perioperative period, drugs were usually nonse-
ective and presented -AR properties (epinephrine, nor-
pinephrine, dobutamine, isoprenaline). Furthermore, it
as admitted that IMA exhibited moderate 1/2-AR
unction, which implied that use of -AR agonists was not
ppropriate to reverse vasospasm (44). Thus, new -AR
gonists with 3-AR agonistic properties might help to
aintain the CABG flow.
The routine use of beta-blockers has been considered for
atients who undergo revascularization after acute myocar-
ial infarction in order to reduce mortality (45). Although
ost patients are rendered asymptomatic after coronary
rtery bypass, there is evidence that blood flow through
MA grafts is inadequate for maximal exercise (46). In a
arge cohort of patients who underwent coronary artery
ypass after myocardial infarction, beta-blockers reduced
ortality (45). It was admitted that the use of a -AR
ntagonist should not evoke IMA vasospasm (21). The
evelopment of a third generation of beta-blockers with
asodilating properties resulting from a 3-AR agonistic
ffect (nebivolol, bucindolol) might constitute an interesting
ew way of investigation (47,48). In isolated human umbil-
cal vein endothelial cells, nebivolol dose-dependently in-
reased NO formation (49). This effect was inhibited by
3-AR blockers, but not by 1/2-AR blockers, suggesting
hat endothelial 3-ARs mediated the increased NO pro-
uction. Furthermore, in rat aorta, nebivolol-induced va-
orelaxation seemed to result from the 3-AR activation
47). All together, those data strengthened the importance
f developing and/or selecting drugs possessing 1-AR
ntagonist and 3-AR agonist properties to manage a large
umber of cardiovascular pathologies (hypertension, heart
ailure).
In conclusion, the present findings highlighted the po-
ential role of 3-ARs in blood flow regulation. Many
ardiovascular pathologies, such as systemic hypertension
nd heart failure, are characterized by a sustained activation
f the sympathetic nervous system. According to their
harmacological properties, 3-ARs could play a potential
ole in those diseases. Thus, the present study opens a new
eld of investigation concerning the involvement of 3-ARs
n human cardiovascular physiopathology and might con-
ribute to the development of new -AR agonists and/or
ntagonists.
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